Advanced glycation endproducts and their receptor in different body compartments in COPD

Respiratory Research

Table 2 AGE and RAGE expression in young and old subjects, and COPD patients

	Young healthy	Old healthy	COPD GOLD I-IV	Kruskal-Wallis
	<40 years	>40 years	>40 years	p-value
Plasma	n = 105	n = 82	n = 95
CEL, μg/ml	10.2 (7.4-15.4)	7.0 (4.8-10.6) **	6.8 (5.1-9.4) **	0.000*
CML, μg/ml	10.5 (0.0-29.5)	9.2 (0.0-13.5) **	12.5 (0.0-21.6) **^a	0.042*
Pentosidine, ng/ml	36.8 (25.3-53.1)	39.9 (30.1-52.0)	46.1 (31.8-58.5)	0.181
sRAGE, pg/ml	795 (614-1089)	805 (617-1032)	414 (292-592) **^a	0.000*
Induced sputum	n = 97	n = 73	n = 12
CEL, μg/ml	5.9 (1.9-8.9)	3.50 (0.0-6.9)	6.0 (2.9-11.0)	0.064
CML, μg/ml	10.6 (0.0-22.7)	10.4 (0.0-23.7)	18.3 (11.2-22.5)	0.409
Pentosidine, ng/ml	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.650
sRAGE, pg/ml	78.1 (0.0-160.2)	114.0 (0.0-240.5)	110.9 (49.7-161.8)	0.117
Bronchial Biopsies	n = 85	n = 68	n = 12
AGEs, positivity (%)	31.1 (20.3-36.9)	25.9 (20.9-35.4)	25.5 (16.9-30.7)	0.418
RAGE, positivity (%)	9.8 (6.5-15.1)	8.2 (5.7-11.8)	8.0 (4.2-11.4)	0.204
Skin	n = 107	n = 83	n = 96
AGE-reader, SAF	1.2 (1.1-1.5) *	1.8 (1.6-2.0) *	2.5 (2.2-2.9) *	0.000*

Data is expressed as median (IQR). * p < 0.05 between all groups, ** p < 0.05 compared with the young healthy group, ^a compared with the old healthy group
CEL N^ε-(carboxyethyl)lysine, CML N^ε-(carboxymethyl)lysine, RAGE receptor for advanced glycation endproducts, AGEs advanced glycation endproducts, SAF skin autofluorescence

ISSN: 1465-993X